机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China,[2]National Clinical Research Center for Hematologic Disease, Beijing, China,[3]Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China,[4]Collaborative Innovation Center of Hematology, Peking University, Beijing, China,[5]Department of Hematology, Qilu Hospital, Shandong University, Jinan, China,[6]Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China,[7]Department of Clinical Epidemiology, Peking University People’s Hospital, Beijing, China,[8]Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China,[9]Department of Hematology, Hainan General Hospital, Haikou, China,[10]Department of Hemotology, West China Hospital, Sichuan University, Chengdu, China,四川大学华西医院[11]Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China,[12]Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China,[13]Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China,[14]Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,河南省肿瘤医院[15]Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China,[16]Department of Hematology, The First Hospital of Jilin University, Changchun, China,[17]Department of Hematology, Lanzhou University Second Hospital, Lanzhou, China,[18]Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China,[19]Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China,[20]Department of Hematology, Beijing Hospital, Ministry of Health, Beijing, China,[21]Department of Hematology, Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China,[22]Department of Hematology, Affiliated Shanxi Big Hospital of Shanxi Medical University, Taiyuan, China,[23]Department of Hematology, Guangzhou First People’s Hospital, Guangzhou, China,[24]Xinqiao Hospital, The Third Military Medical University, Chongqing, China,[25]Department of Hematology, Peking University First Hospital, Beijing, China,[26]Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,[27]Nanfang Hospital, Nanfang Medical University, Guangzhou, China,[28]Beijing Luhe Hospital, Capital Medical University, Beijing, China,[29]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,[30]Fuxing Hospital, Capital Medical University, Beijing, China,[31]Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, China[32]Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
Intracranial hemorrhage (ICH) is a devastating complication of immune thrombocytopenia (ITP). However, information on ICH in ITP patients under the age of 60 years is limited, and no predictive tools are available in clinical practice. A total of 93 adult patients with ITP who developed ICH before 60 years of age were retrospectively identified from 2005 to 2019 by 27 centers in China. For each case, 2 controls matched by the time of ITP diagnosis and the duration of ITP were provided by the same center. Multivariate analysis identified head trauma (OR = 3.216, 95%CI 1.296-7.979, P =.012), a platelet count ≤ 15,000/μL at the time of ITP diagnosis (OR = 1.679, 95%CI 1.044-2.698, P =.032) and severe/life-threatening bleeding (severe bleeding vs. mild bleeding, OR = 1.910, 95%CI 1.088-3.353, P =.024; life-threatening bleeding vs. mild bleeding, OR = 2.620, 95%CI 1.360-5.051, P =.004) as independent risk factors for ICH. Intraparenchymal hemorrhage (OR = 5.191, 95%CI 1.717-15.692, P =.004) and a history of severe bleeding (OR = 4.322, 95%CI 1.532-12.198, P =.006) were associated with the 30-day outcome of ICH. These findings may facilitate ICH risk stratification and outcome prediction in patients with ITP.
基金：
This work was supported by Beijing Municipal Science and Technology
Commission [No. Z171100001017084], National Natural Science
Foundation of China [No. 81970113, No. 81730004 and No.
81670116], Beijing Natural Science Foundation [No.
H2018206423, No. 7171013], the National Key Research and
Development Program of China [No. 2017YFA0105500, No.
2017YFA0105503], and the Foundation for Innovative Research Groups
of the National Natural Science Foundation of China [No. 81621001].
第一作者机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China,[2]National Clinical Research Center for Hematologic Disease, Beijing, China,[3]Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China,[4]Collaborative Innovation Center of Hematology, Peking University, Beijing, China,
共同第一作者：
通讯作者：
通讯机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China,[2]National Clinical Research Center for Hematologic Disease, Beijing, China,[3]Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China,[4]Collaborative Innovation Center of Hematology, Peking University, Beijing, China,
推荐引用方式(GB/T 7714)：
Peng Zhao,Ming Hou,Yi Liu,et al.Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age.[J].PLATELETS.2021,32(5):633-641.doi:10.1080/09537104.2020.1786042.
APA：
Peng Zhao,Ming Hou,Yi Liu,Hui-Xin Liu,Rui-Bin Huang...&the Cooperative ITP Working Group.(2021).Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age..PLATELETS,32,(5)
MLA：
Peng Zhao,et al."Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age.".PLATELETS 32..5(2021):633-641
